Abstract
The creation of commercial cord blood banks rests on the promise of stem cell based regenerative medicine and marks the capitalization of human tissues within a future-oriented ?regime of hope?. This paper will present data from a survey of the international cord blood banking industry and will explore: (a) the way firms seek to commercialize cord blood as a new set of commodities; (b) the expectations and moral economy that are being constructed around this technology; and (c) how firms are acting as mediators of hope in what might be called a ?promissory bioeconomy?.
Original language | English |
---|---|
Pages (from-to) | 127-143 |
Number of pages | 17 |
Journal | New Genetics and Society |
Volume | 27 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2008 |